Cardiovascular Disease After Aromatase Inhibitor Use

Cardiovascular Disease After Aromatase Inhibitor Use

ID:39507486

大小:301.58 KB

页数:8页

时间:2019-07-04

Cardiovascular Disease After Aromatase Inhibitor Use_第1页
Cardiovascular Disease After Aromatase Inhibitor Use_第2页
Cardiovascular Disease After Aromatase Inhibitor Use_第3页
Cardiovascular Disease After Aromatase Inhibitor Use_第4页
Cardiovascular Disease After Aromatase Inhibitor Use_第5页
资源描述:

《Cardiovascular Disease After Aromatase Inhibitor Use》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库

1、ResearchOriginalInvestigationCardiovascularDiseaseAfterAromataseInhibitorUseReinaHaque,PhD;JiaxiaoShi,PhD;JoanneE.Schottinger,MD;JoanieChung,MPH;ChantalAvila,MA;BrittaAmundsen,MA;XiaoqingXu,PharmD;AnaBarac,MD;RowanT.Chlebowski,MDSupplementalcontentatIMPORTANCECardiovascu

2、lardisease(CVD)isanimportantcauseofdeathinolderpatientsjamaoncology.comwithbreastcancer.However,limitedinformationexistsonthelong-termeffectofaromataseinhibitor(AI)useonCVDriskinbreastcancersurvivors.Tothispoint,nootherpopulation-basedstudieshavebeenabletoadjustforCVDris

3、kfactorsorcardiovascularmedications.OBJECTIVETodeterminethelong-terminfluenceofadjuvantendocrinetherapiesonCVDinacohortofpostmenopausalbreastcancersurvivorsinanalysesthataccountedformajorCVDriskfactors,medicationuse,chemotherapy,andradiotherapy.DESIGN,SETTING,ANDPARTICIP

4、ANTSAretrospectivecohortofpostmenopausalwomenwithbreastcancerdiagnosedfromJanuary1,1991,toDecember31,2010,andfollowedupthroughDecember31,2011(maximum,21years[72886person-years]),wasevaluatedusingrecordsfromamanagedcareorganizationwithnearly20communityhospitalsinCaliforni

5、a.Atotalof13273postmenopausalwomenwithhormonereceptor–positivebreastcancerwithoutpriorCVDwereincluded.Cardiovasculardiseaseincidencewascomparedacrossendocrinetherapycategories.Informationondemographics,comorbidity,medication,use,andCVDriskwascapturedfromelectronichealthr

6、ecords.MultivariateCoxproportionalhazardsmodelsusingtime-dependentendocrinedrugusevariablesandpropensityscoreswereconducted.DataanalysiswasconductedfromSeptember15,2014,toFebruary1,2016.EXPOSURESWomenweregroupedbyendocrinetherapystatus(tamoxifencitrateonly,AIonly,both,or

7、neither).MAINOUTCOMESANDMEASURESPerson-yearratesofCVDforeachtherapygroup.RESULTSDuring72886person-yearsin13273women(mean[SD]age,66.8[8.1]years)withfollow-upthrough2011,weobserved3711CVDevents.Inmultivariableanalyses(reportedashazardratio[95%CI]),AI-onlyusershadasimilarri

8、skofcardiacischemia(myocardialinfarctionandangina)(adjusted,0.97[0.78-1.22])andstroke(adjusted,0.97[0.7

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。